Krensavage Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Krensavage Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-112,666	Closed	-$1.78M	–	16
2023 Q3	$1.78M	Sell	112,666 -771	-0.7%	-$13.9K	0.65%	10
2023 Q2	$2.21M	Sell	113,437 -300	-0.3%	-$7.12K	0.7%	12
2023 Q1	$3.23M	Sell	113,737 -1,088	-0.9%	-$32.3K	0.98%	10
2022 Q4	$3.36M	Sell	114,825 -6,258	-5%	-$199K	1.04%	10
2022 Q3	$3.2M	Buy	121,083 +69	+0.1%	+$2.53K	1.02%	12
2022 Q2	$5.38M	Buy	121,014 +6,227	+5%	+$286K	1.78%	11
2022 Q1	$5.68M	Buy	114,787 +8,300	+8%	+$398K	1.96%	9
2021 Q4	$5.42M	Sell	106,487 -1,286	-1%	-$66.6K	1.88%	9
2021 Q3	$6.01M	Buy	107,773 +36,969	+52%	+$1.82M	1.89%	10
2021 Q2	$3.03M	Buy	+70,804	New	+$2.92M	1.03%	10

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Krensavage Asset Management's EGRX Position: Q4 2023 in Review

Krensavage Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 112,666 shares — an estimated $1.78M sold.

Krensavage Asset Management first reported a position in EGRX in Q2 2021 and held it in 10 quarters. The position peaked at $6.01M in Q3 2021. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

Krensavage Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Krensavage Asset Management sold 112,666 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $1.78M.
Krensavage Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2021 and held it in 10 quarters.
Krensavage Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $6.01M in Q3 2021.
104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on Krensavage Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.